FDA grants priority review to relugolix for advanced prostate cancer
The FDA granted priority review to relugolix for treatment of men with advanced prostate cancer. Read here.
Invasive prostate cancer incidence rising among young men; cause elusive
Incidence of prostate cancer among adolescents and young adults has increased in the United States and many other countries during... Read More
Study offers insight into correlation between infertility, prostate cancer risk
Men who fathered children through assisted reproduction methods demonstrated higher risk for prostate cancer and early-onset prostate cancer than men... Read More
High-dose radiation effective in oligometastatic prostate cancer
Stereotactic ablative radiation appeared to be an effective and safe treatment for men with oligometastatic prostate cancer, with significant benefits... Read More
Stereotactic body radiotherapy safe, effective for low to intermediate risk prostate cancer
Stereotactic body radiotherapy induced high rates of biochemical control and low rates of severe toxicity among men with low- or... Read More
Use of Conservative Management for Low-Risk Prostate Cancer ‘Increasing Rapidly’
Conservative management or deferred treatment is the preferred approach for men with low-risk prostate cancer, according to results of a... Read More
Nearly 10% of Patients with Prostate Cancer Lost to Follow Up
Almost one in 10 patients with prostate cancer who were under active surveillance were lost to follow up, according to... Read More
Studies of Immunotherapy for Prostate Cancer Yield Encouraging Results
Several studies designed to investigate immunotherapies and immunotherapeutic combinations for treatment of prostate cancer have yielded encouraging results. “Thus far,... Read More
Finasteride Does Not Increase Risk for Prostate Cancer Death
Previously, the Prostate Cancer Prevention Trial showed finasteride increased the number of high-grade prostate cancers, even as it reduced patients’ overall... Read More
FDA Approves Yonsa for Metastatic Castration-Resistant Prostate Cancer
The FDA approved a novel formulation of abiraterone acetate in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant... Read More